Marta Libura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marta Libura has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Olga Haus
Department of Clinical Genetics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Skłodowskiej - Curie 9, 85-094 Bydgoszcz, Poland
3 shared publications - Agata Filip
Department of Clinical Genetics with Cytogenetic Laboratory, Medical University of Lublin, Radziwillowska St. 11, 20-400 Lublin, Poland
2 shared publications - Izabela Florek
Department of Haematology, Faculty of Medicine Jagiellonian University, 19 Kopernika Str., 31-501 Cracow, Poland
2 shared publications - Katarzyna Borg
Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
2 shared publications - Małgorzata Jakóbczyk
Department of Haematology, Faculty of Medicine Jagiellonian University, 19 Kopernika Str., 31-501 Cracow, Poland
2 shared publications Agata Kominek
Laboratory of Cytometry, Nencki Institute of Experimental Biology, Warsaw, Poland
1 shared publication
Latest Publications
- Open Access
- 11 May 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-13
IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) genes occur in about 20% patients with acute myeloid leukemia (AML), leading to DNA hypermethylation and epigenetic deregulation. We assessed the prognostic significance of IDH1/2 mutations (IDH1/2+) in 398 AML patients with normal karyotype (NK-AML), treated with daunorubicine + cytarabine (DA), DA + cladribine (DAC), or DA + fludarabine. IDH2 mutation was an independent favorable prognostic factor for 4-year overall survival (OS) in total NK-AML population (p = 0.03, censoring at allotransplant). We next evaluated the effect of addition of cladribine to induction regimen on the patients’ outcome according to IDH1/2 mutation status. In DAC group, 4-year OS was increased in IDH2+ patients, compared to IDH-wild type group (54% vs 33%; p = 0.0087, censoring at allotransplant), while no difference was observed for DA-treated subjects. In multivariate analysis, DAC independently improved the survival of IDH2+ patients (HR = 0.6 [0.37–0.93]; p = 0.024; censored at transplant), indicating that this group specifically benefits from cladribine-containing therapy. In AML cells with R140Q or R172K IDH2 mutations, cladribine restrained mutations-related DNA hypermethylation. Altogether, DAC regimen produces better outcomes in IDH2+ NK-AML patients than DA, and this likely results from the hypomethylating activity of cladribine. Our observations warrant further investigations of induction protocols combining cladribine with IDH1/2 inhibitors in IDH2-mutant.
- 11 May 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-13
Open AccessIDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) genes occur in about 20% patients with acute myeloid leukemia (AML), leading to DNA hypermethylation and epigenetic deregulation. We assessed the prognostic significance of IDH1/2 mutations (IDH1/2+) in 398 AML patients with normal karyotype (NK-AML), treated with daunorubicine + cytarabine (DA), DA + cladribine (DAC), or DA + fludarabine. IDH2 mutation was an independent favorable prognostic factor for 4-year overall survival (OS) in total NK-AML population (p = 0.03, censoring at allotransplant). We next evaluated the effect of addition of cladribine to induction regimen on the patients’ outcome according to IDH1/2 mutation status. In DAC group, 4-year OS was increased in IDH2+ patients, compared to IDH-wild type group (54% vs 33%; p = 0.0087, censoring at allotransplant), while no difference was observed for DA-treated subjects. In multivariate analysis, DAC independently improved the survival of IDH2+ patients (HR = 0.6 [0.37–0.93]; p = 0.024; censored at transplant), indicating that this group specifically benefits from cladribine-containing therapy. In AML cells with R140Q or R172K IDH2 mutations, cladribine restrained mutations-related DNA hypermethylation. Altogether, DAC regimen produces better outcomes in IDH2+ NK-AML patients than DA, and this likely results from the hypomethylating activity of cladribine. Our observations warrant further investigations of induction protocols combining cladribine with IDH1/2 inhibitors in IDH2-mutant.
- 1 December 2015
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 55 (4) , 284-292
CEBPA copy number variations in normal karyotype acute myeloid leukemia: Possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis
- 1 December 2015
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 55 (4) , 284-292
CEBPA copy number variations in normal karyotype acute myeloid leukemia: Possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis
- 1 July 2014
- Published by Elsevier in Leukemia Research
- Vol. 38 (7) , 850-856
Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients
- 1 July 2014
- Published by Elsevier in Leukemia Research
- Vol. 38 (7) , 850-856
Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients
- 30 June 2012
- Published by Springer Nature
- p. 387-410
Molecular Diagnostics of Acute Myeloblastic Leukemia
- 30 June 2012
- Published by Springer Nature
- p. 387-410
Molecular Diagnostics of Acute Myeloblastic Leukemia
- 30 June 2012
- Published by Springer Nature
- p. 29-53
Genetic Mechanisms and Molecular Markers of Neoplastic Transformation in Acute Myeloid Leukemia
- 30 June 2012
- Published by Springer Nature
- p. 29-53
Genetic Mechanisms and Molecular Markers of Neoplastic Transformation in Acute Myeloid Leukemia